# Dabrafenib and/or Trametinib Rollover Study

> **NCT03340506** · PHASE4 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Melanoma
- Non Small Cell Lung Cancer
- Solid Tumor
- Rare Cancers
- High Grade Glioma

## Interventions

- **DRUG:** dabrafenib
- **DRUG:** trametinib

## Key facts

- **NCT ID:** NCT03340506
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-28
- **Primary completion:** 2032-12-28
- **Final completion:** 2032-12-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03340506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03340506, "Dabrafenib and/or Trametinib Rollover Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03340506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*